Brokers Offer Predictions for InflaRx FY2026 Earnings

InflaRx (NASDAQ:IFRX) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of InflaRx in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will post earnings of ($0.65) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $10.00 price objective on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share.

A number of other equities analysts also recently weighed in on the stock. Guggenheim upped their price target on shares of InflaRx from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, March 26th. Oppenheimer lowered their target price on InflaRx from $6.00 to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, May 29th. Raymond James lowered InflaRx from a “strong-buy” rating to an “outperform” rating and set a $2.00 target price on the stock. in a research report on Thursday, May 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of InflaRx in a research note on Friday, March 21st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $6.60.

InflaRx Stock Down 1.2%

IFRX stock opened at $0.84 on Tuesday. The company has a 50 day moving average of $1.29 and a two-hundred day moving average of $1.77. The company has a market cap of $56.39 million, a price-to-earnings ratio of -0.78 and a beta of 1.29. InflaRx has a 12-month low of $0.71 and a 12-month high of $2.82.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IFRX. Northern Trust Corp increased its position in InflaRx by 1,933.1% during the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock worth $1,647,000 after buying an additional 634,045 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock worth $119,000 after acquiring an additional 11,900 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of InflaRx in the 4th quarter valued at approximately $1,576,000. Cubist Systematic Strategies LLC bought a new position in shares of InflaRx in the fourth quarter valued at approximately $55,000. Finally, Commonwealth Equity Services LLC lifted its stake in shares of InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after buying an additional 19,000 shares during the last quarter. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.